883 related articles for article (PubMed ID: 17620823)
21. Association between HLA-B Alleles and Carbamazepine-Induced Maculopapular Exanthema and Severe Cutaneous Reactions in Thai Patients.
Sukasem C; Chaichan C; Nakkrut T; Satapornpong P; Jaruthamsophon K; Jantararoungtong T; Koomdee N; Sririttha S; Medhasi S; Oo-Puthinan S; Rerkpattanapipat T; Klaewsongkram J; Rerknimitr P; Tuchinda P; Chularojanamontri L; Tovanabutra N; Puangpetch A; Aekplakorn W
J Immunol Res; 2018; 2018():2780272. PubMed ID: 29546073
[TBL] [Abstract][Full Text] [Related]
22. Pharmacogenetics of cutaneous adverse drug reactions.
Aihara M
J Dermatol; 2011 Mar; 38(3):246-54. PubMed ID: 21342226
[TBL] [Abstract][Full Text] [Related]
23. HLA associations and clinical implications in T-cell mediated drug hypersensitivity reactions: an updated review.
Cheng CY; Su SC; Chen CH; Chen WL; Deng ST; Chung WH
J Immunol Res; 2014; 2014():565320. PubMed ID: 24901010
[TBL] [Abstract][Full Text] [Related]
24. Stevens-Johnson syndrome, drug-induced hypersensitivity syndrome and toxic epidermal necrolysis caused by allopurinol in patients with a common HLA allele: what causes the diversity?
Dainichi T; Uchi H; Moroi Y; Furue M
Dermatology; 2007; 215(1):86-8. PubMed ID: 17587850
[No Abstract] [Full Text] [Related]
25. Association of carbamazepine-induced severe cutaneous drug reactions and HLA-B*1502 allele status, and dose and treatment duration in paediatric neurology patients in Singapore.
Chong KW; Chan DW; Cheung YB; Ching LK; Hie SL; Thomas T; Ling S; Tan EC
Arch Dis Child; 2014 Jun; 99(6):581-4. PubMed ID: 24225276
[TBL] [Abstract][Full Text] [Related]
26. Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions.
Amstutz U; Shear NH; Rieder MJ; Hwang S; Fung V; Nakamura H; Connolly MB; Ito S; Carleton BC;
Epilepsia; 2014 Apr; 55(4):496-506. PubMed ID: 24597466
[TBL] [Abstract][Full Text] [Related]
27. Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China.
Wu XT; Hu FY; An DM; Yan B; Jiang X; Kwan P; Stefan H; Zhou D
Epilepsy Behav; 2010 Nov; 19(3):405-8. PubMed ID: 20833111
[TBL] [Abstract][Full Text] [Related]
28. HLA Allele Frequencies in 5802 Koreans: Varied Allele Types Associated with SJS/TEN According to Culprit Drugs.
Park HJ; Kim YJ; Kim DH; Kim J; Park KH; Park JW; Lee JH
Yonsei Med J; 2016 Jan; 57(1):118-26. PubMed ID: 26632391
[TBL] [Abstract][Full Text] [Related]
29. Genetic predisposition of life-threatening antiepileptic-induced skin reactions.
Chung WH; Hung SI; Chen YT
Expert Opin Drug Saf; 2010 Jan; 9(1):15-21. PubMed ID: 20001755
[TBL] [Abstract][Full Text] [Related]
30. Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand.
Rattanavipapong W; Koopitakkajorn T; Praditsitthikorn N; Mahasirimongkol S; Teerawattananon Y
Epilepsia; 2013 Sep; 54(9):1628-38. PubMed ID: 23895569
[TBL] [Abstract][Full Text] [Related]
31. Pharmacogenetics of allopurinol--making an old drug safer.
Lam MP; Yeung CK; Cheung BM
J Clin Pharmacol; 2013 Jul; 53(7):675-9. PubMed ID: 23381951
[TBL] [Abstract][Full Text] [Related]
32. Genetic and immune predictors for hypersensitivity syndrome to antiepileptic drugs.
Neuman MG; Cohen L; Nanau RM; Hwang PA
Transl Res; 2012 May; 159(5):397-406. PubMed ID: 22500513
[TBL] [Abstract][Full Text] [Related]
33. Initiating allopurinol therapy: do we need to know the patient's human leucocyte antigen status?
Lee MH; Stocker SL; Anderson J; Phillips EJ; Nolan D; Williams KM; Graham GG; Sullivan JR; Day RO
Intern Med J; 2012 Apr; 42(4):411-6. PubMed ID: 21790926
[TBL] [Abstract][Full Text] [Related]
34. Diagnostic utility of HLA-B*5801 screening in severe allopurinol hypersensitivity syndrome: an updated systematic review and meta-analysis.
Yu KH; Yu CY; Fang YF
Int J Rheum Dis; 2017 Sep; 20(9):1057-1071. PubMed ID: 28857441
[TBL] [Abstract][Full Text] [Related]
35. Oxcarbazepine-induced Stevens-Johnson syndrome: a case report.
Lin LC; Lai PC; Yang SF; Yang RC
Kaohsiung J Med Sci; 2009 Feb; 25(2):82-6. PubMed ID: 19321411
[TBL] [Abstract][Full Text] [Related]
36. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review.
Yip VL; Marson AG; Jorgensen AL; Pirmohamed M; Alfirevic A
Clin Pharmacol Ther; 2012 Dec; 92(6):757-65. PubMed ID: 23132554
[TBL] [Abstract][Full Text] [Related]
37. Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions.
Hung SI; Chung WH; Jee SH; Chen WC; Chang YT; Lee WR; Hu SL; Wu MT; Chen GS; Wong TW; Hsiao PF; Chen WH; Shih HY; Fang WH; Wei CY; Lou YH; Huang YL; Lin JJ; Chen YT
Pharmacogenet Genomics; 2006 Apr; 16(4):297-306. PubMed ID: 16538176
[TBL] [Abstract][Full Text] [Related]
38. Pharmacogenetic markers of severe cutaneous adverse drug reactions.
Borroni RG
G Ital Dermatol Venereol; 2014 Apr; 149(2):219-26. PubMed ID: 24819643
[TBL] [Abstract][Full Text] [Related]
39. HLA and drug-induced toxicity.
Phillips EJ; Mallal SA
Curr Opin Mol Ther; 2009 Jun; 11(3):231-42. PubMed ID: 19479656
[TBL] [Abstract][Full Text] [Related]
40. Pharmacogenetic information derived from analysis of HLA alleles.
Gatanaga H; Honda H; Oka S
Pharmacogenomics; 2008 Feb; 9(2):207-14. PubMed ID: 18370849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
